» Articles » PMID: 30144455

Orbital Lymphoma

Overview
Journal Surv Ophthalmol
Specialty Ophthalmology
Date 2018 Aug 26
PMID 30144455
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Orbital lymphomas constitute 50-60% of ocular adnexal lymphomas. A total of 2211 cases of orbital lymphoma with a known subtype have been reported in the last 24 years (1994-2017). The vast majority of orbital lymphomas are of B-cell origin (97%), of which extranodal marginal zone B-cell lymphoma (EMZL) (59%) is the most common subtype, followed by diffuse large B-cell lymphoma (23%), follicular lymphoma (9%), and mantle cell lymphoma (5%). Orbital lymphoma is primarily a disease of the elderly. Gender distribution varies according to lymphoma subtype. However, extranodal marginal zone B-cell lymphoma (53%) and follicular lymphoma (75%) show a female predominance, whereas diffuse large B-cell lymphoma shows an even gender distribution. Mantle cell lymphoma has a striking male predominance of 80%. The histopathological subtype and the clinical stage of the disease are the best indicators of prognosis and patient outcome. Low-grade lymphomas such as extranodal marginal zone B-cell lymphoma and FL have a good prognosis, whereas high-grade lymphomas (diffuse large B-cell lymphoma and mantle cell lymphoma) are associated with a poor prognosis. When managing solitary low-grade lymphomas, radiotherapy is the treatment of choice. Chemotherapy, with or without radiotherapy, should be chosen for disseminated and high-grade lymphomas.

Citing Articles

Single-cell RNA-sequencing reveals cellular heterogeneity and immune microenvironment characteristics between ocular adnexal mucosa-associated lymphoid lymphoma and IgG4-related ophthalmic disease.

Yang Y, Wang Y, Jin X, He W Front Immunol. 2025; 16:1508559.

PMID: 40078987 PMC: 11897659. DOI: 10.3389/fimmu.2025.1508559.


Extranodal natural killer/T-cell lymphoma with secondary haemophagocytic lymphohistiocytosis simulating orbital inflammatory disease.

Lee J, Moynihan V, Mesbah Ardakani N, Gajdatsy A BMJ Case Rep. 2025; 18(2).

PMID: 39914863 PMC: 11800070. DOI: 10.1136/bcr-2024-259848.


[New systemic treatment approach for primary lymphoma of the orbit and the ocular adnexa].

Niederau C, Wawer Matos Reimer P, Rokohl A, Heindl L Ophthalmologie. 2025; .

PMID: 39808278 DOI: 10.1007/s00347-024-02169-4.


Imaging analysis of ocular involvement in granulomatosis with polyangiitis.

Tang S, Zhang Y, Wang H, Li H, Li J Quant Imaging Med Surg. 2024; 14(12):9820-9829.

PMID: 39698630 PMC: 11652059. DOI: 10.21037/qims-24-239.


Safety and efficacy of intralesional rituximab injection versus involved site radiation therapy in primary ocular adnexal MALT lymphoma: study protocol for a multicentre randomised controlled trial.

Liu Y, Gao Y, Jin L, Li Q, Wang X, Wu Y BMJ Open. 2024; 14(11):e084904.

PMID: 39608989 PMC: 11603821. DOI: 10.1136/bmjopen-2024-084904.